Nautilus NeurosciencesNews » Nautilus Neurosciences

News

Nautilus Neurosciences, Inc. Announces the Sale of CAMBIA® (Diclofenac Potassium for Oral Solution) to Depomed, Inc. for Total Consideration of Up to $53.7 Million

Bedminster, NJ – December 17, 2013 – Nautilus Neurosciences, Inc. has completed a transaction for the sale of the U.S. and Canadian rights to CAMBIA® (diclofenac potassium for oral solution) to Depomed, Inc. (NASDAQ: DEPO). CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) indicated for acute treatment of migraine attacks with or without aura in adults…

Top

Nautilus Neurosciences, Inc. Announces Co-Promotion Agreement for Lorzone™

BEDMINSTER, NJ – June 11, 2013 – Nautilus Neurosciences, Inc., a CNS-focused specialty pharmaceutical company, is pleased to announce that we have entered into a partnership with Vertical Pharmaceuticals (Sayreville, NJ) to co-promote Lorzone™ to Nautilus’ customers.  Lorzone™ is a safe and effective muscle relaxant containing the active ingredient chlorzoxazone.  Under the terms of the…

Top

Nautilus Neurosciences Appoints Peter Lankau as Executive Chairman

BEDMINSTER, NJ – November 8, 2011 – Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company headquartered in Bedminster, New Jersey, announced today that Peter A. Lankau has joined the company as Executive Chairman of the Board of Directors. Mr. Lankau will have an active role in the company and will focus primarily on business strategy…

Top
Page 1 of 1

Keep up to date with everything Nautilus.

We like to be intimately engaged with our customers. Sign up for our newsletter here.